Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1987 2
2010 2
2011 4
2013 1
2014 3
2015 2
2016 1
2017 1
2018 1
2019 4
2020 4
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: kendra kl. J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880964 Free PMC article. Clinical Trial.
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Grossman D, et al. Among authors: kendra kl. JAMA Dermatol. 2020 Sep 1;156(9):1004-1011. doi: 10.1001/jamadermatol.2020.1729. JAMA Dermatol. 2020. PMID: 32725204 Free PMC article. Review.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Atkins MB, et al. Among authors: kendra kl. J Clin Oncol. 2022 Sep 27:JCO2201763. doi: 10.1200/JCO.22.01763. Online ahead of print. J Clin Oncol. 2022. PMID: 36166727
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Jeter JM, et al. Among authors: kendra kl. Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Cancer. 2019. PMID: 30281145 Free PMC article. Review.
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.
Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ. Johns AC, et al. Among authors: kendra kl. J Geriatr Oncol. 2021 Jun;12(5):813-819. doi: 10.1016/j.jgo.2021.02.002. Epub 2021 Feb 21. J Geriatr Oncol. 2021. PMID: 33627226 Free PMC article.
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: kendra kl. J Immunother Cancer. 2021 May;9(5):e002535. doi: 10.1136/jitc-2021-002535. J Immunother Cancer. 2021. PMID: 33963015 Free PMC article. Clinical Trial.
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.
Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE. Suarez-Kelly LP, et al. Among authors: kendra kl. Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6. Cancer Immunol Immunother. 2019. PMID: 30725205 Free PMC article. Clinical Trial. No abstract available.
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL. Moschos SJ, et al. Among authors: kendra kl. Melanoma Res. 2021 Apr 1;31(2):162-172. doi: 10.1097/CMR.0000000000000726. Melanoma Res. 2021. PMID: 33661190 Free PMC article. Clinical Trial.
29 results